CCSD Code A7350: Peripheral Nerve Block Procedures

Key Takeaways

CCSD A7350 covers five peripheral nerve block types for UK private healthcare

Each block requires documented diagnostic or therapeutic medical necessity

Pre-authorisation requirements vary by insurer and nerve block location

Healthcode submission demands procedure-specific anatomical site coding

Local anaesthetic type and volume must be documented for all blocks

CCSD code A7350 covers peripheral nerve block procedures commonly performed in UK private pain management and musculoskeletal clinics. This single code encompasses five distinct nerve block types: occipital nerve blocks for headache and occipital neuralgia, sphenopalatine ganglion blocks for facial pain syndromes, intercostal nerve blocks for chest wall pain, suprascapular nerve blocks for shoulder pain, and trigeminal nerve blocks for facial neuralgia. Each requires specific anatomical documentation and varies in pre-authorisation requirements across UK private insurers.

The clinical rationale for CCSD A7350 procedures centres on diagnostic confirmation or therapeutic pain relief through targeted local anaesthetic injection. Occipital nerve blocks primarily treat chronic headache disorders and occipital neuralgia, while sphenopalatine blocks address atypical facial pain and cluster headache syndromes. Intercostal blocks manage post-surgical pain, rib fractures, and neuropathic chest wall pain. Suprascapular blocks target shoulder pain from rotator cuff pathology or adhesive capsulitis. Trigeminal blocks address facial pain from trigeminal neuralgia or post-herpetic neuralgia affecting facial nerve branches.

What Is CCSD Code A7350?

CCSD A7350 describes peripheral nerve blockade procedures where a clinician injects local anaesthetic adjacent to a specific nerve to achieve temporary sensory interruption. The CCSD schedule defines this code as covering multiple anatomical sites under a single procedure classification, unlike CPT coding systems that assign separate codes per nerve location. UK private insurers recognise A7350 for both diagnostic blocks (initial assessment) and therapeutic blocks (pain management interventions).

Diagnostic nerve blocks using A7350 require initial local anaesthetic injection to confirm suspected nerve-mediated pain. If temporary pain relief occurs, the block confirms the nerve as the pain generator. Therapeutic blocks may follow diagnostic confirmation, often using longer-acting local anaesthetics or adjuvant medications. Bupa’s code search system lists A7350 alongside required diagnostic codes and typical fee schedules, which vary by UK region and insurer contract terms.

The code applies when clinicians perform the procedure under local anaesthetic without sedation. When performed under general anaesthetic or with imaging guidance (fluoroscopy or ultrasound), additional CCSD codes may apply. Documentation must specify the nerve blocked, local anaesthetic agent, volume administered, and patient response to justify medical necessity for both initial and repeat procedures.

CCSD A7350: Common Peripheral Nerve Block Procedures

Five nerve block procedures fall under CCSD A7350, each targeting distinct anatomical structures. Understanding the clinical indications, anatomical landmarks, and documentation requirements for each block type ensures accurate coding and pre-authorisation success with UK private insurers.

CCSD A7350: Occipital Nerve Block (Greater and Lesser Occipital Nerves)

Occipital nerve blocks target the greater occipital nerve (medial branch of C2 dorsal ramus) and lesser occipital nerve (branch of cervical plexus) for headache management and occipital neuralgia. Clinicians perform these blocks when patients present with unilateral or bilateral occipital pain radiating from the skull base toward the vertex, often triggered by neck movement or pressure over the occipital region. Aviva’s fee schedule requires documented failed conservative management (analgesics, physiotherapy) before authorising initial blocks.

The procedure involves palpating the occipital artery at the superior nuchal line, then injecting 2-5ml of local anaesthetic medial to the artery for greater occipital nerve block. Lesser occipital blocks target the nerve lateral to the occipital artery. Documentation must record injection site, local anaesthetic type and volume, immediate pain response, and duration of relief. Bupa typically authorises three diagnostic blocks before considering prognostic nerve ablation procedures.

CCSD A7350: Sphenopalatine Ganglion Block

Sphenopalatine ganglion blocks address cluster headaches, atypical facial pain, and migraine syndromes resistant to pharmacological management. The sphenopalatine ganglion sits in the pterygopalatine fossa, accessible via transnasal or transoral approaches. Transnasal techniques use cotton-tipped applicators soaked in local anaesthetic, advanced along the middle turbinate to reach the posterior nasal cavity. Documentation must specify approach method, local anaesthetic concentration, application duration, and headache response within 24 hours.

VitalityHealth’s fee finder system requires prior headache diary documentation showing attack frequency and failed preventive medication trials. The clinical note should detail headache classification (cluster, migraine, atypical facial pain) and previous treatment failures. Repeat blocks for chronic conditions typically need re-authorisation every three months with documented pain score improvements.

CCSD A7350: Intercostal Nerve Block

Intercostal nerve blocks manage chest wall pain from post-thoracotomy neuralgia, rib fractures, post-herpetic neuralgia affecting thoracic dermatomes, or chronic musculoskeletal chest pain. Clinicians inject local anaesthetic at the inferior border of the affected rib, targeting the intercostal nerve between the internal and innermost intercostal muscles. Multiple-level blocks may be performed for extensive pain distributions, with each level requiring separate documentation.

AXA Health’s procedure code portal classifies single-level and multi-level intercostal blocks under the same A7350 code but adjusts fee schedules based on the number of levels injected. Documentation should specify rib levels blocked (e.g., T5-T8), local anaesthetic volume per level, and whether bilateral blocks were performed. Pre-authorisation for post-surgical intercostal blocks often receives automatic approval when linked to recent thoracic procedures within the same insurer network.

CCSD A7350: Suprascapular Nerve Block

Suprascapular nerve blocks target chronic shoulder pain from rotator cuff disease, adhesive capsulitis, or subacromial impingement syndrome unresponsive to physiotherapy and oral medications. The suprascapular nerve provides sensory innervation to the shoulder joint and motor supply to supraspinatus and infraspinatus muscles. Blocks are performed at the suprascapular notch, superior to the scapular spine, using anatomical landmarks or ultrasound guidance.

WPA’s medical fee guidance requires documented range-of-motion limitations and MRI evidence of shoulder pathology before authorising suprascapular blocks. The clinical note must detail shoulder examination findings (active and passive range of motion in all planes), rotator cuff strength testing results, and failure of at least six weeks of conservative management. Some insurers bundle suprascapular blocks with glenohumeral joint injections under combined shoulder intervention codes, requiring clarification during pre-authorisation.

CCSD A7350: Trigeminal Nerve Block (Supraorbital, Infraorbital, Mental Nerve)

Trigeminal nerve blocks address facial pain from trigeminal neuralgia affecting specific nerve branches, post-herpetic neuralgia following facial shingles, or chronic facial pain syndromes. The three main branches-ophthalmic (V1), maxillary (V2), and mandibular (V3)-are accessed via superficial injection points: supraorbital notch for V1, infraorbital foramen for V2, and mental foramen for V3. Each branch may be blocked individually or in combination depending on pain distribution.

Cigna UK’s fee schedule system requires diagnostic code alignment with facial pain topography-V1 blocks need documented periorbital pain, V2 blocks require cheek or upper lip pain, and V3 blocks must correspond to lower lip or jaw pain. Documentation should specify which trigeminal branch was blocked, local anaesthetic volume (typically 1-2ml per branch), and whether multiple branches were injected during the same session. Repeat blocks need re-authorisation with documented pain diary improvements.

CCSD A7350 Documentation Requirements for UK Private Practice

Accurate clinical documentation determines whether UK private insurers approve and reimburse CCSD A7350 procedures. Each nerve block requires specific anatomical details, medical necessity justification, and procedural technique descriptions. Missing documentation elements trigger claim rejections or payment delays.

The clinical note must state the exact nerve blocked using anatomical terminology recognised by the CCSD schedule. Generic descriptions like “nerve block for pain” fail pre-authorisation requirements. Instead, specify “greater occipital nerve block” or “left infraorbital nerve block for trigeminal neuralgia affecting the maxillary division.” Include the patient’s pain location, duration, character, and functional impact. Document failed conservative treatments with dates and specific interventions attempted (medication names, physiotherapy sessions, injection therapies).

Procedural documentation must detail the local anaesthetic agent (lignocaine, bupivacaine, or ropivacaine), concentration, total volume administered, and whether adjuvant medications (steroids, clonidine) were added. Record the injection technique (landmark-based or ultrasound-guided), number of injection attempts, and immediate patient response. Digital consent forms streamline nerve block documentation by auto-populating procedural details and capturing electronic patient signatures before treatment begins.

Post-procedure notes should document pain score changes (using numerical rating scales), duration of pain relief, and any adverse effects. For diagnostic blocks, record whether temporary pain relief occurred and the time course of relief. This information justifies progressing from diagnostic to therapeutic blocks or considering alternative interventions. Healix’s fee schedule portal cross-references diagnostic block outcomes when approving therapeutic block claims, rejecting authorisations when initial blocks showed no benefit.

CCSD A7350 Pre-Authorisation and Healthcode Submission Workflows

UK private insurers apply varying pre-authorisation requirements for CCSD A7350 procedures based on clinical indication, nerve block type, and whether the procedure is diagnostic or therapeutic. Understanding insurer-specific workflows prevents claim rejections and reduces administrative burden for private practices.

Bupa requires pre-authorisation for all initial nerve blocks under A7350 when performed outside of immediate post-operative settings. The authorisation request must include the diagnostic code justifying the block, documentation of failed conservative management, and the specific nerve to be blocked. Bupa’s system cross-references the diagnostic code with approved indications-occipital blocks require headache diagnoses, intercostal blocks need chest wall pain codes, and trigeminal blocks must align with facial pain or neuralgia diagnoses. Claims management features in modern practice software auto-populate these requirements from the patient record, reducing manual data entry during pre-authorisation submission.

Aviva distinguishes between diagnostic and therapeutic blocks, requiring separate authorisations for each. A diagnostic occipital nerve block receives initial approval for up to three attempts over six months. If diagnostic blocks confirm nerve-mediated pain (documented by temporary pain relief), therapeutic blocks need re-authorisation with evidence from the diagnostic phase. The therapeutic authorisation request must include pain diary data showing attack frequency before and after diagnostic blocks, plus a treatment plan outlining how many therapeutic blocks are proposed.

Healthcode submission for A7350 procedures demands anatomical site specificity beyond the CCSD code itself. The electronic claim must include the procedure code (A7350), the anatomical site modifier indicating which nerve was blocked, and the diagnostic code explaining medical necessity. Allianz Care’s UK fee schedule publishes site-specific fee variations-trigeminal blocks typically reimburse at lower rates than sphenopalatine blocks due to procedural complexity differences. Missing anatomical site modifiers trigger system rejections, requiring claim resubmission and delaying payment by 2-4 weeks.

For practices treating patients across multiple insurers, maintaining insurer-specific workflow documentation becomes critical. VitalityHealth accepts electronic pre-authorisation via their provider portal, while WPA requires telephone authorisation for all first-time nerve blocks. Some clinics use automated workflow software to route pre-authorisation requests to the correct insurer channel based on the patient’s insurance details captured during booking.

Common CCSD A7350 Claim Denials and How to Avoid Them

CCSD A7350 claims face rejection for preventable documentation gaps, coding errors, and pre-authorisation mismatches. Systematic claim audit reveals four recurring denial patterns across UK private insurers.

Medical necessity denials occur when the clinical note fails to justify why the nerve block was required. Insurers reject claims when documentation shows insufficient conservative management before proceeding to interventional procedures. A claim stating “chronic headache, performed occipital nerve block” without listing failed treatments (analgesics, triptans, preventive medications, physiotherapy) typically results in “not medically necessary” denials. The fix requires documentation templates prompting clinicians to record specific failed treatments with dates and dosages before nerve block procedures.

Anatomical site mismatches between the diagnostic code and nerve block location trigger automatic system rejections. An infraorbital nerve block (trigeminal V2 branch) paired with an occipital pain diagnostic code fails logic validation during Healthcode processing. The diagnostic code must align with the anatomical distribution of the blocked nerve-trigeminal blocks need facial pain codes, intercostal blocks require chest wall pain codes, and occipital blocks must show headache or occipital neuralgia diagnoses. Cross-referencing the diagnostic code with nerve innervation territories before submitting claims prevents this denial type.

Pre-authorisation expiration denials occur when clinics perform procedures after the authorisation validity window closes. Bupa authorisations typically remain valid for 60 days from approval date, while Aviva extends validity to 90 days for planned therapeutic block series. If a patient reschedules beyond the authorisation window, practices must request authorisation renewal before performing the procedure. Claims submitted with expired authorisation numbers receive automatic denials, requiring full re-authorisation and delaying payment by 4-6 weeks. Setting up calendar alerts 14 days before authorisation expiry prompts practices to either complete the procedure or request extension.

Documentation incompleteness denials stem from missing procedural details insurers need to validate the claim. A note stating “performed nerve block under local anaesthesia” without specifying which nerve was blocked, what local anaesthetic was used, or how the patient responded fails minimum documentation standards. Insurers return these claims marked “insufficient information for adjudication,” requiring amended notes and claim resubmission. Structured clinical documentation templates with mandatory fields for nerve name, local anaesthetic type and volume, injection technique, and patient response prevent incomplete documentation denials.

Streamline CCSD A7350 Billing Workflows

See how Pabau automates nerve block documentation, pre-authorisation tracking, and Healthcode claim submission for UK private practices. Book a demo to explore insurer-specific workflow templates and automated denial prevention checks.

Book a demo

CCSD A7350 Billing Considerations for Multi-Site Practices

Private practices operating across multiple UK locations face additional CCSD A7350 billing complexity when clinicians perform nerve blocks at different sites. Insurer contracts often specify which practice locations hold authorisation to perform interventional procedures, creating geographic restrictions on where A7350 claims may originate.

Bupa’s provider network agreements designate specific clinic addresses as “interventional procedure sites” versus “consultation-only sites.” A practice with three locations might hold interventional authorisation for only two sites, meaning nerve blocks performed at the third location generate automatic claim denials even when properly pre-authorised. The denial reason states “procedure performed at non-approved facility,” requiring the practice to resubmit the claim under a different clinic location code or appeal the denial with evidence that the procedure met clinical standards regardless of location.

Multi-site practices must maintain location-specific CCSD coding workflows, ensuring claims submitted under A7350 include the correct facility identifier for each insurer’s records. AXA Health’s systems link facility identifiers to provider registration numbers, validating that the registered practitioner operates at an approved interventional site. When a practitioner performs nerve blocks at multiple practice locations, each site needs separate registration with the insurer, adding administrative overhead during initial provider onboarding but preventing claim rejections during live billing.

Some insurers adjust A7350 reimbursement rates based on practice location within the UK. Central London practices typically receive higher fee schedules than practices in other regions, reflecting local operating cost variations. Aviva publishes regional fee multipliers in their annual fee schedule updates, with London Zone 1 practices receiving up to 1.3× base rates compared to practices in other UK regions. Multi-site groups spanning multiple regions must track which rate applies to each claim based on service location, not the practice’s registered headquarters address. Multi-location management features in practice software automatically apply location-specific fee schedules during claim generation, reducing manual rate lookup requirements.

UK Private Insurer Fee Schedules for CCSD A7350

CCSD A7350 reimbursement rates vary significantly across UK private insurers, with fee differences reaching 40% between highest and lowest payers for identical procedures. Understanding fee schedule structures helps practices set appropriate pricing strategies and manage patient financial expectations.

Bupa publishes regional A7350 fee schedules differentiating between diagnostic and therapeutic blocks. A diagnostic greater occipital nerve block in London Zone 1 typically reimburses at £180-220, while the same procedure outside London reimburses at £140-180. Therapeutic blocks using longer-acting local anaesthetics with steroid adjuvants receive 15-20% higher reimbursement rates due to increased medication costs and procedural complexity. Bupa’s fee finder system displays both base rates and regional multipliers, allowing practices to calculate expected reimbursement before submitting claims.

Aviva applies a tiered fee structure based on whether nerve blocks are performed with imaging guidance. Standard A7350 procedures using anatomical landmark techniques reimburse at base rates, while ultrasound-guided blocks qualify for additional imaging guidance fees coded separately under CCSD imaging codes. The combined reimbursement for ultrasound-guided occipital blocks can reach £280-320 in London, compared to £180-220 for landmark-based techniques. However, the imaging guidance fee requires documented medical necessity-Aviva rejects imaging guidance claims when the clinical note doesn’t explain why landmark techniques were insufficient.

AXA Health’s fee schedules bundle certain nerve block combinations under single A7350 payments rather than reimbursing per nerve blocked. Bilateral occipital nerve blocks receive 1.5× the unilateral block rate, not 2× as practices might expect. Similarly, performing multiple trigeminal branch blocks during the same session (e.g., supraorbital and infraorbital) receives bundled payment rather than separate reimbursement per branch. The fee schedule documentation clarifies which combinations qualify for bundled versus separate payment, but practices must review these policies annually as insurers modify bundling rules during contract renewals.

VitalityHealth, WPA, Healix, and Allianz Care publish their fee schedules with different update frequencies. VitalityHealth updates fees quarterly, WPA updates annually each January, and Healix negotiates fees during individual provider contract renewals rather than publishing standard rates. This variability requires practices to maintain insurer-specific fee reference databases, updating rates as new schedules release. Practices that fail to track fee schedule changes may submit claims at outdated rates, receiving partial payment with the balance written off as contractual adjustments. Automated payment reconciliation tools flag fee schedule mismatches by comparing submitted claim amounts against current insurer fee databases, alerting practices to rate discrepancies before they result in underpayment.

Expert Insights: Optimising CCSD A7350 Workflows

Expert Picks

Need to improve nerve block billing accuracy? Digital Forms auto-populate anatomical site details and local anaesthetic documentation during procedure consent, reducing incomplete documentation denials by capturing required fields before clinicians leave the treatment room.

Struggling with multi-insurer pre-authorisation tracking? Automated Workflows route pre-authorisation requests to the correct insurer portal based on patient insurance details, set expiry reminders, and flag when authorisations near expiration before scheduled nerve block appointments.

Want to reduce Healthcode submission errors? Claims Management Software validates CCSD codes against diagnostic codes before submission, ensuring anatomical site alignment and catching medical necessity documentation gaps that trigger automatic denials.

Conclusion

CCSD code A7350 covers five peripheral nerve block procedures commonly performed in UK private pain management practices, each requiring specific anatomical documentation, medical necessity justification, and insurer-specific pre-authorisation workflows. Occipital, sphenopalatine, intercostal, suprascapular, and trigeminal nerve blocks share a single CCSD code but differ in clinical indications, documentation requirements, and reimbursement rates across UK private insurers. Systematic documentation practices, insurer-specific authorisation tracking, and accurate Healthcode claim submission prevent the most common denial patterns affecting A7350 procedures.

Private practices operating across multiple UK locations face geographic restrictions on where nerve blocks may be performed, requiring facility-specific insurer approvals and location-aware fee schedule application. Multi-site groups must maintain reference systems mapping which practice locations hold interventional procedure authorisation with each insurer, preventing claim denials from procedures performed at unauthorised facilities. Regional fee variations further complicate multi-location billing, with London-based practices receiving up to 30% higher reimbursement than practices in other UK regions for identical A7350 procedures.

Understanding insurer-specific nuances-Bupa’s diagnostic versus therapeutic block authorisation requirements, Aviva’s imaging guidance policies, AXA’s bundled payment rules-ensures practices capture full reimbursement while maintaining compliance with contractual billing standards. Integrating these requirements into practice management workflows through structured documentation templates, automated pre-authorisation tracking, and real-time claim validation reduces administrative burden and improves first-pass claim acceptance rates for A7350 procedures.

Frequently Asked Questions